Next Article in Journal
The Role of Combined Penetration Enhancers in Nasal Microspheres on In Vivo Drug Bioavailability
Next Article in Special Issue
Calcium Phosphate Spacers for the Local Delivery of Sitafloxacin and Rifampin to Treat Orthopedic Infections: Efficacy and Proof of Concept in a Mouse Model of Single-Stage Revision of Device-Associated Osteomyelitis
Previous Article in Journal
Selected Medicines Used in Iontophoresis
Previous Article in Special Issue
Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies
Open AccessReview

Targeted Nanomedicine to Treat Bone Metastasis

J. Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville 32611, FL, USA
*
Author to whom correspondence should be addressed.
Pharmaceutics 2018, 10(4), 205; https://doi.org/10.3390/pharmaceutics10040205
Received: 30 August 2018 / Revised: 15 October 2018 / Accepted: 23 October 2018 / Published: 25 October 2018
(This article belongs to the Special Issue Bone Targeted Drug Delivery)
Bone metastases are common complications of solid tumors, particularly those of the prostate, breast, and lungs. Bone metastases can lead to painful and devastating skeletal-related events (SREs), such as pathological fractures and nerve compressions. Despite advances in treatment for cancers in general, options for bone metastases remain inadequate and generally palliative. Anticancer drugs (chemotherapy and radiopharmaceuticals) do not achieve therapeutic concentrations in the bone and are associated with dose-limiting side effects to healthy tissues. Nanomedicines, with their tunable characteristics, have the potential to improve drug targeting to bone metastases while decreasing side effects for their effective treatment. In this review, we present the current state of the art for nanomedicines to treat bone metastases. We also discuss new treatment modalities enhanced by nanomedicine and their effects on SREs and disease progression. View Full-Text
Keywords: drug delivery; bone marrow; passive targeting; active targeting; nanoparticle drug delivery; bone marrow; passive targeting; active targeting; nanoparticle
Show Figures

Graphical abstract

MDPI and ACS Style

Adjei, I.M.; Temples, M.N.; Brown, S.B.; Sharma, B. Targeted Nanomedicine to Treat Bone Metastasis. Pharmaceutics 2018, 10, 205.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop